Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arlo-cel (BMS-986393) vs Standard Regimens in Relapsed or Refractory Multiple Myeloma
NCT06615479Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of arlocabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression Free Survival up to 5 years and Minimal residual disease-negativity in complete response up to 1 year. Started Mar 2025; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06615479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615479.